An anticancer drug known as Rapamycin acts by inhibiting the mammalian target of the
Rapamycin pathway. This agent has recently been investigated for its potential therapeutic …

Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor
prognosis, lacking therapeutic targets. miRNAs play crucial roles in TNBC through …

Triple‐negative breast cancer, devoid of estrogen (ER), progesterone (PR), and human
epidermal growth factor receptor 2 (HER‐2) expression, is deprived of commonly used …

SKBR3-cells, characterized by ERBB2/RARA co-amplification, represent a subgroup of
HER2+ breast-cancers sensitive to all-trans retinoic acid (ATRA) and Lapatinib. In this …

Breast cancer is one of the primary threats to women's health worldwide. However, the
molecular mechanisms underlying the development of breast cancer remain to be fully …

Background: Chemotherapy is the main treatment for triple-negative breast cancer (TNBC),
which lack molecular markers for diagnosis and therapy. Cancer cells activate …

The present study aimed to identify the differentially expressed genes (DEGs) and enriched
pathways in docetaxel (DTX) resistant breast cancer cell lines by bioinformatics analysis …

Background: miRNAs (microRNAs) play a key role in triple-negative breast cancer (TNBC)
progression, and its heterogeneity at the expression, pathological and clinical levels …

Breast cancer threatens women's health. Although there are a lot of methods to treat breast
cancer, chemotherapy resistance still hinders the effectiveness of treatment. This study …

Breast cancer (BC) is the most widespread cancer worldwide. Over 2 million new cases of
BC were identified in 2020 alone. Despite previous studies, the lack of specific biomarkers …